Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors [PDF]
Therapeutic Advances in Medical Oncology, 2019 Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC).
Chiara Casadei +7 more
doaj +3 more sources
Network Dynamics Caused by Genomic Alteration Determine the Therapeutic Response to FGFR Inhibitors for Lung Cancer [PDF]
Biomolecules, 2022 Recently, FGFR inhibitors have been highlighted as promising targeted drugs due to the high prevalence of FGFR1 amplification in cancer patients. Although various potential biomarkers for FGFR inhibitors have been suggested, their functional effects have
Jonghoon Lee +2 more
doaj +2 more sources
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer. [PDF]
Cancer Discov, 2023 Abstract Several fibroblast growth factor receptor (FGFR) inhibitors are approved or in clinical development for the treatment of FGFR-driven urothelial cancer, and molecular mechanisms of resistance leading to patient relapses have not been fully explored.
Facchinetti F +21 more
europepmc +4 more sources
Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors [PDF]
Cancer Control, 2021 Objective: Intrahepatic cholangiocarcinoma (iCCA), the second most common type of primary liver tumor, has an increasing incidence in the past few decades. iCCA is highly malignant, with a 5-year survival rate of approximately 5-10%.
Tianyu Wu MD +7 more
doaj +2 more sources
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer [PDF]
BMC Cancer, 2022 Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the development
Andrew J. Weickhardt +8 more
doaj +2 more sources
Efficacy and safety of first- versus second-generation fibroblast growth factor receptor (FGFR) inhibitors in advanced or metastatic urothelial carcinoma with FGFR alterations: a systematic review and meta-analysis [PDF]
Frontiers in PharmacologyIntroductionWe reviewed the clinical studies on fibroblast growth factor receptor (FGFR) inhibitors for the treatment of urothelial carcinoma to conduct the meta-analysis of clinical efficacy and safety, aiming to provide more precise treatment options ...
Zhe Wang +3 more
doaj +2 more sources
FGFR inhibitors promote the autophagic degradation of IFN-γ-induced PD-L1 and alleviate the PD-L1-mediated transcriptional suppression of FGFR3-TACC3 in non-muscle-invasive bladder cancer [PDF]
Cell Death and DiseaseBladder cancer (BC) is the second most prevalent genitourinary malignancy worldwide. Treatment options remain limited for patients with Bacillus Calmette–Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC).
Yu-Chen Lin +6 more
doaj +2 more sources
Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors [PDF]
Communications Chemistry, 2022 The human fibroblast growth factor receptors (FGFRs) are attractive targets for cancer therapy, but the structural basis for kinase targeting and gatekeeper mutations of covalent FGFR inhibitors are not fully understood.
Lingzhi Qu +9 more
doaj +2 more sources
FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors. [PDF]
Neurooncol AdvAbstract A wide spectrum of genomic events leading to dysregulated fibroblast growth factor receptor (FGFR) signaling have been reported across low-grade and high-grade glial/glioneuronal tumors. These events include structural alterations, such as gene fusions and duplications, as well as recurrent mutations in FGFR1–3.
Sait SF, Bale T, Karajannis MA.
europepmc +4 more sources
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice [PDF]
Cancers, 2021 Milind Javle +2 more
exaly +2 more sources